Featured Company News - NeuroMetrix Announces Issuance of New US Patent for Automated Control of Quell(R) Therapy During Sleep
Research Desk Line-up: DENTSPLY SIRONA Post Earnings Coverage
LONDON, UK / ACCESSWIRE / August 17, 2017 /Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for NeuroMetrix, Inc. (NASDAQ: NURO), following which we have published a free report that can be viewed by signing up at http://protraderdaily.com/optin/?symbol=NURO. NeuroMetrix declared on August 15, 2017, that the US Patent and Trademark Office has issued US Patent No. 9,731,126. This patent covers an innovative technology wherein NeuroMetrix's Quell® device automatically modulates therapeutic neurostimulation based on the user's sleep characteristics. The patent also includes claims related to providing device users with feedback about their sleep. For immediate access to our complimentary reports, including today's coverage, register for free now at:
Discover more of our free reports coverage from other companies within the Medical Instruments & Supplies industry. Pro-TD has currently selected DENTSPLY SIRONA Inc. (NASDAQ: XRAY) for due-diligence and potential coverage as the Company announced on August 09, 2017, its financial results for Q2 2017 which ended on June 30, 2017. Tune in to our site to register for a free membership, and be among the early birds that get our report on DENTSPLY SIRONA when we publish it.
At Pro-TD, we make it our mission to bring you news that matter about the stock you follow. Today, our research desk covers a blog story on NURO; also brushing on XRAY. Go directly to your stock of interest and access today's free coverage at:
Inadequate Sleep Aggravates Pain
Most of the people with chronic pain experience sleep disorders, mostly insomnia. Inadequate sleep aggravates pain symptoms, which in turn leads to a vicious cycle of decreased activity during the day and lesser sleep at night. Quell® addresses the impact of chronic pain on sleep. In fact, it is the only transcutaneous electrical nerve stimulator cleared by the FDA for use during sleep, which is available over the counter. It measures and tracks sleep data, which helps users understand the amount and quality of their sleep. Users can also access their sleep measurements on the Quell® smartphone app and Quell® Health Cloud.
Wearable Technology that Treats Chronic Pain during Sleep
Quell® has been designed for millions of people suffering from chronic pain. It comes in the form of an advanced lightweight wearable device. It can be worn during the day while active as well as at night while sleeping. Quell® is integrated into a digital health platform that helps patients optimize their therapy and decrease the impact of chronic pain on their quality of life. It offers its users the flexibility to personalize and manage therapy discreetly via the Quell® Relief app. It also provides advanced health tracking, which is particularly relevant for chronic pain sufferers including pain, sleep, activity, and gait.
According to a recent study, around 81% of Quell® users confirmed an improvement in their chronic pain. Quell was the winner of the 2016 South by Southwest (SXSW) Innovation Award for Best Wearable Technology. Moreover, FDA has approved Quell® for treatment of chronic pain without a prescription.
Quell® is available at select healthcare professionals and retailers. More detailed information about the device is available on the website QuellRelief.com.
Patent Expands Competitive Position of NeuroMetrix
Shai N. Gozani, Ph.D. and M.D. at NeuroMetrix, reaffirmed that chronic pain can severely disrupt one's quality of life. For a lot of people, pain increases throughout the day and peaks at night. And these higher levels of pain prevent one from getting to sleep and also staying asleep. Shai N. Gozani expressed his pleasure on receiving the latest patent for automated regulation of Quell therapy during sleep. He mentioned that this patent would further expand the wearable pain relief intellectual property assets of NeuroMetrix and strengthen its long-term competitive position.
NeuroMetrix is a leading commercial-stage, innovation-driven healthcare Company. It is located in Waltham, Massachusetts and was founded as a spinoff from the Harvard-MIT Division of Health Sciences and Technology in 1996. The Company addresses chronic health conditions such as sleep disorders, chronic pain, and diabetes by combining neurostimulation and digital medicine. It seeks to maintain an active research effort and has several pipeline programs.
Last Close Stock Review
On Wednesday, August 16, 2017, NeuroMetrix's stock closed the trading session at $1.87, climbing 3.89% from its previous closing price of $1.80. A total volume of 3.62 thousand shares were exchanged during the session. The stock currently has a market cap of $3.96 million.
Pro-Trader Daily (Pro-TD) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. PRO-TD has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles, and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
PRO-TD has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email firstname.lastname@example.org. Rohit Tuli, a CFA® charter holder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by PRO-TD. PRO-TD is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
PRO-TD, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. PRO-TD, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, PRO-TD, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither PRO-TD nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://protraderdaily.com/disclaimer/.
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: (917) 341.4653
Office Address: Mainzer Landstrasse 50 Frankfurt am Main, Germany 60325
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
© 2017 Accesswire. All Rights Reserved.